[1]Taro Inks $36M Investor Deal Over Generics Price-Fixing

   By Lauren Berg

   Taro Pharmaceutical Industries shareholders asked a New York federal
   judge Monday to greenlight a $36 million settlement resolving proposed
   class claims that the company misled investors about alleged generic
   drug price-fixing that led to a drop in stock price upon news of a U.S.
   Department of Justice antitrust investigation.

   [icon-pdf.png]  Motion attached | [2]Read full article » | [3]Save to
   favorites »

References

   1. https://www.law360.com/competition/articles/1825670?nl_pk=6416fd97-1dc4-4e02-b7d8-a89ca44ecaf4&utm_source=newsletter&utm_medium=email&utm_campaign=competition&utm_content=2024-04-16&read_main=1&nlsidx=0&nlaidx=1
   2. https://www.law360.com/competition/articles/1825670?nl_pk=6416fd97-1dc4-4e02-b7d8-a89ca44ecaf4&utm_source=newsletter&utm_medium=email&utm_campaign=competition&utm_content=2024-04-16&read_more=1&nlsidx=0&nlaidx=1
   3. https://www.law360.com/competition/articles/1825670?nl_pk=6416fd97-1dc4-4e02-b7d8-a89ca44ecaf4&utm_source=newsletter&utm_medium=email&utm_campaign=competition&utm_content=2024-04-16&read_later=1&nlsidx=0&nlaidx=1